Last reviewed · How we verify
NUCS
NUCS is a small molecule that targets the SARS-CoV-2 main protease.
NUCS is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | NUCS |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
NUCS works by binding to the SARS-CoV-2 main protease, thereby inhibiting the viral replication. This mechanism of action is crucial in the treatment of COVID-19. The exact binding affinity and specificity of NUCS to the SARS-CoV-2 main protease are still being studied.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B (PHASE2)
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (PHASE1)
- Study of LW231 in Participants With Chronic Hepatitis B (PHASE1, PHASE2)
- Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. (PHASE1)
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (PHASE3)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NUCS CI brief — competitive landscape report
- NUCS updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI